Nolato AB announced it has signed a long-term cooperation agreement with a major existing customer to supply medical devices for drug administration, including to support treatment of obesity and diabetes. The supply agreement will have no material impact on Nolato?s sales and profit over the next two years. At full-scale production, within a five-year period, it is estimated that this cooperation will generate annual sales in the region of SEK 700 million for Nolato.

The cooperation will result in Nolato investing, from the second quarter of 2024, a total of around SEK 600 million in new manufacturing capacity by expanding existing premises, machinery and other equipment. Around one-fifth of the total amount will be invested during the current year.